| Program ID | Indication | Development Stage | Collaboration Status | |||
|---|---|---|---|---|---|---|
| Hit | Lead | PCC | IND | |||
| SPD02 | Solid tumors |
|
||||
| SY2030 | Prevention of deep vein thrombosis |
|
||||
| SY2031 | Thyroid eye disease |
|
||||
| SY2052 | Dermatitis and fibrosis |
|
||||
| SY2301 | Acute myeloid leukemia (AML) |
|
||||
| SY2342 | Thyroid eye disease |
|
||||
| SY2360 | Non-small cell lung cancer (NSCLC) |
|
||||
| SYP1001 | Eosinophil-related diseases |
|
||||
| XY1494 | Relapsed/refractory multiple myeloma |
|
||||
| XY1603 | Atopic dermatitis |
|
||||
| XY1707 | Myeloablative conditioning |
|
CD3×GPRC5D bispecific antibody
OSMR monoclonal antibody
CCL11 monoclonal antibody
CD117 monoclonal antibody
FXI biparatopic bispecific antibody
IL-31Rα monoclonal antibody